Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia.
Testicular adrenal rest tumors (TARTs)
congenital adrenal hyperplasia (CAH)
ultrasonography (US)
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
ppublish
Résumé
Testicular adrenal rest tumors (TARTs) are benign neoplasms affecting patients with congenital adrenal hyperplasia (CAH). The prevalence of TART in adult patients with CAH is not well known. Ultrasonography (US) is the main tool for diagnosing TART and the role of contrast-enhanced US (CEUS) is never investigated. The aim of this study was to evaluate the TART prevalence in adults with CAH, by stratifying patients according to disease phenotype and assessing the diagnostic performance of US, color Doppler (CD) US and CEUS. Male patients >16 years old with certain diagnosis of CAH who underwent US for TARTs, between December 2015 and September 2019 were prospectively enrolled. The control group included patients without CAH affected by testicular lesions at US other than TARTs. TARTs were identified in 16 of 52 patients (31%), of whom 15 (93.8%) displayed the salt-wasting (SW) form (P<0.001). The prevalence of TARTs in patients with the SW form was 54%. One patient with the non-classic (NC) form (6%) showed TART (likely the first documented case). The mean age of patients upon detection of TARTs was significantly younger compared with the control group (P<0.001); moreover, TARTs were bilateral in 15/16 patients (93.8%; P<0.001) and the largest lesion was more frequent in the medium third of testis in the TART group (87.5%), statistically different from the control group (P=0.013). TARTs almost exclusively affected patients with the SW form of CAH. Age at diagnosis and bilateralism are useful factors for achieving a correct diagnosis of TARTs in CAH adult patients.
Sections du résumé
BACKGROUND
BACKGROUND
Testicular adrenal rest tumors (TARTs) are benign neoplasms affecting patients with congenital adrenal hyperplasia (CAH). The prevalence of TART in adult patients with CAH is not well known. Ultrasonography (US) is the main tool for diagnosing TART and the role of contrast-enhanced US (CEUS) is never investigated. The aim of this study was to evaluate the TART prevalence in adults with CAH, by stratifying patients according to disease phenotype and assessing the diagnostic performance of US, color Doppler (CD) US and CEUS.
METHODS
METHODS
Male patients >16 years old with certain diagnosis of CAH who underwent US for TARTs, between December 2015 and September 2019 were prospectively enrolled. The control group included patients without CAH affected by testicular lesions at US other than TARTs.
RESULTS
RESULTS
TARTs were identified in 16 of 52 patients (31%), of whom 15 (93.8%) displayed the salt-wasting (SW) form (P<0.001). The prevalence of TARTs in patients with the SW form was 54%. One patient with the non-classic (NC) form (6%) showed TART (likely the first documented case). The mean age of patients upon detection of TARTs was significantly younger compared with the control group (P<0.001); moreover, TARTs were bilateral in 15/16 patients (93.8%; P<0.001) and the largest lesion was more frequent in the medium third of testis in the TART group (87.5%), statistically different from the control group (P=0.013).
CONCLUSIONS
CONCLUSIONS
TARTs almost exclusively affected patients with the SW form of CAH. Age at diagnosis and bilateralism are useful factors for achieving a correct diagnosis of TARTs in CAH adult patients.
Identifiants
pubmed: 33718059
doi: 10.21037/tau-20-998
pii: tau-10-02-562
pmc: PMC7947447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
562-573Informations de copyright
2021 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-998). The authors have no conflicts of interest to declare.
Références
Endocrine. 2015 Sep;50(1):32-50
pubmed: 26082286
J Clin Endocrinol Metab. 2017 Feb 1;102(2):339-344
pubmed: 27901643
Pol J Radiol. 2017 Oct 20;82:583-588
pubmed: 29662589
J Endocr Soc. 2019 Oct 17;3(12):2290-2294
pubmed: 31745525
Endocr Pathol. 2017 Jun;28(2):146-151
pubmed: 28032206
J Clin Endocrinol Metab. 2015 Jun;100(6):2303-13
pubmed: 25822101
Am J Med Sci. 2012 Nov;344(5):363-73
pubmed: 22270393
J Urol. 1997 Apr;157(4):1460-3
pubmed: 9120982
Korean J Hepatol. 2010 Sep;16(3):338-41
pubmed: 20924220
Eur J Endocrinol. 2018 Mar;178(3):285-294
pubmed: 29339528
J Clin Endocrinol Metab. 2015 Mar;100(3):E524-30
pubmed: 25485724
J Clin Endocrinol Metab. 2010 May;95(5):2013-4
pubmed: 20444929
Clin Endocrinol (Oxf). 2011 Dec;75(6):753-9
pubmed: 21689130
Urology. 2019 Jul;129:24-28
pubmed: 30898461
J Clin Endocrinol Metab. 2012 Dec;97(12):4429-38
pubmed: 22990093
Clin Radiol. 2005 Sep;60(9):953-9
pubmed: 16124976
Endocrine. 2019 Dec;66(3):695-698
pubmed: 31227992
Eur J Endocrinol. 2007 Sep;157(3):339-44
pubmed: 17766717
J Pediatr Endocrinol Metab. 2015 Sep;28(9-10):1187-90
pubmed: 25879317
Eur J Pediatr. 2017 Oct;176(10):1393-1404
pubmed: 28879515
Medicine (Baltimore). 2015 Sep;94(36):e1471
pubmed: 26356704
Eur J Endocrinol. 2015 Apr;172(4):491-9
pubmed: 25609776
Eur Radiol. 2003 Jul;13(7):1597-603
pubmed: 12835972
J Clin Endocrinol Metab. 2018 Nov 1;103(11):4043-4088
pubmed: 30272171
J Clin Endocrinol Metab. 2009 May;94(5):1665-70
pubmed: 19258407
Eur J Endocrinol. 2016 Jul;175(1):73-84
pubmed: 27129361
Endocr Connect. 2018 Apr;7(4):544-552
pubmed: 29531157
J Clin Endocrinol Metab. 2007 Sep;92(9):3674-80
pubmed: 17595257
Andrologia. 2016 Feb;48(1):45-50
pubmed: 25880899
Endocr Rev. 2019 Aug 1;40(4):973-987
pubmed: 30882882
J Clin Endocrinol Metab. 2001 Jul;86(7):3070-8
pubmed: 11443169
Eur J Endocrinol. 2008 Oct;159(4):489-91
pubmed: 18647821
Gynecol Endocrinol. 2018 Aug;34(8):644-646
pubmed: 29460643
J Ultrasound Med. 2012 Mar;31(3):383-8
pubmed: 22368128
Mol Cell Endocrinol. 2017 Apr 15;445:55-64
pubmed: 27940302
Mol Cell Endocrinol. 2018 Feb 5;461:105-111
pubmed: 28870780
Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):181-92
pubmed: 19500762
J Clin Endocrinol Metab. 2001 Dec;86(12):5721-8
pubmed: 11739428
Horm Res Paediatr. 2014;82(4):238-44
pubmed: 25195868
J Clin Endocrinol Metab. 2007 Feb;92(2):612-5
pubmed: 17090637
J Ultrasound Med. 2004 Jul;23(7):979-81
pubmed: 15292569
Ann Pediatr Endocrinol Metab. 2015 Sep;20(3):155-61
pubmed: 26512352
Reprod Med Biol. 2017 Oct 17;17(1):93-97
pubmed: 29371828
Pediatr Surg Int. 2005 Oct;21(10):853-5
pubmed: 16180005
J Urol. 2017 Mar;197(3 Pt 2):931-936
pubmed: 27840017
Int J Androl. 2010 Jun 1;33(3):521-7
pubmed: 19531083